Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

93 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
CCL5 as an adjuvant for cancer immunotherapy.
Lapteva N, Huang XF. Lapteva N, et al. Expert Opin Biol Ther. 2010 May;10(5):725-33. doi: 10.1517/14712591003657128. Expert Opin Biol Ther. 2010. PMID: 20233026 Review.
A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.
Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM. Narayanan P, et al. Among authors: lapteva n. J Clin Invest. 2011 Apr;121(4):1524-34. doi: 10.1172/JCI44327. Epub 2011 Mar 7. J Clin Invest. 2011. PMID: 21383499 Free PMC article.
Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.
Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF. Lapteva N, et al. J Immunother. 2009 Feb-Mar;32(2):145-56. doi: 10.1097/CJI.0b013e318193d31e. J Immunother. 2009. PMID: 19238013 Free PMC article.
An essential role for Akt1 in dendritic cell function and tumor immunotherapy.
Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. Park D, et al. Among authors: lapteva n. Nat Biotechnol. 2006 Dec;24(12):1581-90. doi: 10.1038/nbt1262. Epub 2006 Dec 3. Nat Biotechnol. 2006. PMID: 17143278
Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer.
Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM. Sonpavde G, et al. Among authors: lapteva n. Cancer Immunol Immunother. 2017 Oct;66(10):1345-1357. doi: 10.1007/s00262-017-2027-6. Epub 2017 Jun 12. Cancer Immunol Immunother. 2017. PMID: 28608115 Clinical Trial.
Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples.
Lyon D, Lapteva N, Gee AP. Lyon D, et al. Among authors: lapteva n. Mol Ther. 2018 Jan 3;26(1):6-7. doi: 10.1016/j.ymthe.2017.12.003. Epub 2017 Dec 9. Mol Ther. 2018. PMID: 29301109 Free PMC article. No abstract available.
Activation and suppression of renin-angiotensin system in human dendritic cells.
Lapteva N, Ide K, Nieda M, Ando Y, Hatta-Ohashi Y, Minami M, Dymshits G, Egawa K, Juji T, Tokunaga K. Lapteva N, et al. Biochem Biophys Res Commun. 2002 Aug 9;296(1):194-200. doi: 10.1016/s0006-291x(02)00855-0. Biochem Biophys Res Commun. 2002. PMID: 12147250
Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells.
Omer B, Castillo PA, Tashiro H, Shum T, Huynh MTA, Cardenas M, Tanaka M, Lewis A, Sauer T, Parihar R, Lapteva N, Schmueck-Henneresse M, Mukherjee M, Gottschalk S, Rooney CM. Omer B, et al. Among authors: lapteva n. Front Med (Lausanne). 2018 Dec 11;5:343. doi: 10.3389/fmed.2018.00343. eCollection 2018. Front Med (Lausanne). 2018. PMID: 30619856 Free PMC article.
SOCS1 downregulation in dendritic cells promotes memory T-cell responses.
Aldrich M, Sanders D, Lapteva N, Huang XF, Chen SY. Aldrich M, et al. Among authors: lapteva n. Vaccine. 2008 Feb 20;26(8):1128-35. doi: 10.1016/j.vaccine.2007.11.020. Epub 2007 Dec 7. Vaccine. 2008. PMID: 18222020 Free PMC article.
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM. Tanaka M, et al. Among authors: lapteva n. Clin Cancer Res. 2017 Jul 15;23(14):3499-3509. doi: 10.1158/1078-0432.CCR-16-2138. Epub 2017 Feb 9. Clin Cancer Res. 2017. PMID: 28183713 Free PMC article. Clinical Trial.
93 results
Jump to page